(9ci)-5-甲基-1-己烯-2-醇 | 724413-91-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: (9ci)-5-甲基-1-己烯-2-醇
• 英文名称: 5-Methylhex-1-en-2-ol
• CAS: 724413-91-6
• 化学式: C₇H₁₄O
• 分子量: 114.19
• InChiKey: FJCCLTIVLXDIRG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• SYNTHETIC BILE ACID COMPOSITIONS AND METHODS
  申请人：Kythera Biopharmaceutical, Inc.

  公开号：US20130190283A1

  公开（公告）日：2013-07-25

  Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.

  胆汁酸及其相关组成物的合成和使用方法。更具体地说，脱氧胆酸及其相关组成物，所述组成物不含任何动物来源的基团和不含热原性基团。
• BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE
  申请人：MEDIVATION TECHNOLOGIES, INC.

  公开号：US20130190303A1

  公开（公告）日：2013-07-25

  This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及可用于调节组织胺受体的新化合物。其中描述了新的桥接杂环[4,3-b]吲哚化合物。还提供了制药组合物，包括含有该化合物的制药组合物。还提供了使用该化合物进行各种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• FUSED TETRACYCLIC PYRIDO [4,3-B] INDOLE AND PYRIDO [3,4-B] INDOLE DERIVATIVES AND METHODS OF USE
  申请人：Chakravarty Sarvajit

  公开号：US20130210803A1

  公开（公告）日：2013-08-15

  This disclosure is directed to fused tetracyclic pyrido[4,3-b]indoles and pyrido[3,4-b]indoles. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.

  本公开涉及熔合四环吡啶[4,3-b]吲哚和吡啶[3,4-b]吲哚。还提供了包含这些化合物的制药组合物，以及使用这些化合物进行多种治疗应用的方法，包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
• Small Molecule Inhibitors of Ebola and Lassa Fever Viruses
  申请人：Cunningham James

  公开号：US20140329834A1

  公开（公告）日：2014-11-06

  The present invention relates to compositions and methods for the treatment of infection by enveloped viruses, such as Ebola and Lassa fever viruses.

  本发明涉及用于治疗被包膜病毒感染，如埃博拉和拉沙热病毒的组合物和方法。
• COMPOSITIONS AND METHODS RELATING TO SALTS OF SPECIALIZED PRO-RESOLVING MEDIATORS OF INFLAMMATION
  申请人：Thetis Pharmaceuticals LLC

  公开号：EP3795179A1

  公开（公告）日：2021-03-24

  The present invention relates to compounds of Formulas I-IV, which are salts of special lipid mediators of inflammation, compositions containing same, and methods of using same in the treatment of various diseases and disorders characterized by chronic or excessive inflammation, or both.

  本发明涉及作为炎症特殊脂质介质盐的式 I-IV 的化合物、含有这些化合物的组合物，以及使用这些化合物治疗以慢性或过度炎症或两者兼有为特征的各种疾病和失调的方法。